Interní Med. 2019; 21(2): 112-116 | DOI: 10.36290/int.2019.017

Ezetimibe in the treatment of hypercholesterolaemia

doc. MUDr. David Karásek, Ph.D.
III. interní klinika – nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc

Currently, the primary aim of lipid‑ lowering treatment is focused on reduction of LDL‑ cholesterol, because there is a compelling evidence for association between its decrease and the decline of cardiovascular events. Ezetimibe in combination with statins effectively reduces the levels of atherogenic lipids and, in particular for high‑ risk individuals, this therapy is associated with significant reduction of cardiovascular risk. This therapy is very well tolerated and current availability of a fixed combination of ezetimibe and statins improves patient’s compliance with treatment and increases the likelihood of achieving lipids targets in a broad spectrum of treated population.

Keywords: ezetimibe, simvastatin, atorvastatin, rosuvastatin, LDL‑cholesterol, cardiovascular risk, atherosclerosis

Published: May 10, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karásek D. Ezetimibe in the treatment of hypercholesterolaemia. Interní Med. 2019;21(2):112-116. doi: 10.36290/int.2019.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nutescu EA, Shapiro NL. Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 2003; 11: 1463-1474. Go to original source... Go to PubMed...
    2. Van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000; 129: 1748-1754. Go to original source... Go to PubMed...
    3. Bultas J. Ezetimib - selektivní inhibitor absorpce cholesterolu. Remedia 2004; 14: 214-216.
    4. http://www.sukl.cz/download/spc/SPC1994.pdf
    5. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-1204. Go to original source... Go to PubMed...
    6. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415-427. Go to original source... Go to PubMed...
    7. Karásek D. Diabetická dyslipidemie. Maxdorf 2018; 181 stran.
    8. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009; 265: 568-580. Go to original source... Go to PubMed...
    9. Foody JM, Toth PP, Tershoakovec TM et al. Efficacy and safety of ezetimibe plus atorvastatin therapy. Clin Lipidol 2014; 9: 441-470. Go to original source...
    10. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012; 223: 251-261. Go to original source... Go to PubMed...
    11. Catapano A, Brady WE, King TR, Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005; 21: 1123-1130. Go to original source... Go to PubMed...
    12. Ballantyne CM, Houri J, Notarbartolo A et al.; Ezetimibe Study Group. Effect of ezetimibem coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415. Go to original source... Go to PubMed...
    13. Conard SE, Bays HE, Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008; 102: 1489-1494. Go to original source... Go to PubMed...
    14. Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008; 102: 1495-1501. Go to original source... Go to PubMed...
    15. Stein E, Stender S, Mata P, et al.; Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148: 447-455. Go to original source... Go to PubMed...
    16. Zieve F, Wenger NK, Ben-Yehuda O, et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or = 65 years of age (from the ZETia in the ELDerly (ZETELD) study). Am J Cardiol 2010; 105: 656-663. Go to original source... Go to PubMed...
    17. Bays HE, Averna M, Majul C, et al. Efficacy and safety of ezetimibe addend to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol 2013; 112: 1885-1895. Go to original source... Go to PubMed...
    18. Ballantyne CM, Hoogeveen RC, Raya JL, et al.; GRAVITY Study Investigators. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis 2014; 232: 86-93. Go to original source... Go to PubMed...
    19. Ballantyne CM, Weiss R, Moccetti T, et al.; EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673-680. Go to original source... Go to PubMed...
    20. Gagné C, Gaudet D, Bruckert E, et al.; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469-2475. Go to original source... Go to PubMed...
    21. Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-1443. Go to original source... Go to PubMed...
    22. Denke M, Pearson T, McBride P, et al. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 2006; 3: 93-102. Go to original source... Go to PubMed...
    23. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006; 81: 1579-1588. Go to original source... Go to PubMed...
    24. Tsujita K, Sugiyama S, Sumida H et al.; PRECISE-IVUS Investigators. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol 2015; 66: 495-507. Go to original source... Go to PubMed...
    25. Hougaard M, Hansen HS, Thayssen P et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc Revasc Med 2017; 18: 110-117. Go to original source... Go to PubMed...
    26. Masuda J, Tanigawa T, Yamada T, et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J 2015; 56: 278-285. Go to original source... Go to PubMed...
    27. Luo P, Wang L, Zhu H et al. Impact of Atorvastatin Combined with Ezetimibe for the Treatment of Carotid Atherosclerosis in Patients with Coronary Heart Disease. Acta Cardiol Sin 2016; 32: 578-585.
    28. Wang J, Ai XB, Wang F et al. Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Int Angiol 2017; 36: 467-473. Go to original source... Go to PubMed...
    29. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with karotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 2012; 220: 128-133. Go to original source... Go to PubMed...
    30. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192. Go to original source... Go to PubMed...
    31. Rosseb? AB, Pedersen TR, Boman K, et al.; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-1356. Go to original source... Go to PubMed...
    32. Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387-2397. Go to original source... Go to PubMed...
    33. Giugliano RP, Cannon CP, Blazing MA, et al.; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2018; 137: 1571-1582. Go to original source... Go to PubMed...
    34. Bonaca MP, Gutierrez JA, Cannon C, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol 2018; 6: 934-943. Go to original source... Go to PubMed...
    35. Simon TG, Corey KE, Cannon CP, et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol 2018; 270: 245-252. Go to original source... Go to PubMed...
    36. Eisen A, Cannon CP, Blazing MA, et al.; IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J 2016; 37: 3576-3584. Go to original source... Go to PubMed...
    37. Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol 2017; 69: 911-921. Go to original source... Go to PubMed...
    38. Navar AM, Roe MT, White JA, et al. Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes 2019; 12: e005041. Go to original source... Go to PubMed...
    39. Catapano AL, Graham I, De Backer G, et al.; Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37: 2999-3058. Go to original source... Go to PubMed...
    40. Luo L, Yuan X, Huang W et al. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. Intern Med J 2015; 45: 546-557. Go to original source... Go to PubMed...
    41. Češka R, Táborský M, Vrablík M. Společné stanovisko odborných společností k předepisování PCSK9-inhibitorů. AtheroRev 2018; 3: 161-168.
    42. Takase H, Dohi Y, Okado T, et al. Effects of ezetimibu on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest 2012; 42: 1287-1294. Go to original source... Go to PubMed...
    43. Hiramitsu S, Miyagishima K, Ishii J, et al. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol 2012; 60: 395-400. Go to original source... Go to PubMed...
    44. Krysiak R, Zmuda W, Okopien B. The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Cardiovasc Ther 2014; 32: 40-46. Go to original source... Go to PubMed...
    45. Jellinger PS, Handelsman Y, Rosenblit PD, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract 2017; 23(Suppl 2): 1-87. Go to original source... Go to PubMed...
    46. Vodonos A, Ostapenko I, Toledano R et al. Statin adherence and LDL cholesterol levels. Should we assess adherence prior to statin upgrade? Eur J Intern Med 2015; 26: 268-272. Go to original source... Go to PubMed...
    47. Ho PM, Magid DJ, Shetterly SM et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008; 155: 772-779. Go to original source... Go to PubMed...
    48. Hennekens CH. Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations. Am J Cardiovasc Drugs. 2008; 8: 155-160. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.